<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did XLO's expenses trend impact its Q4 2024 revenue?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 05:18am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Xilio Therapeutics (XLO) reported total revenues of $1.72 million for Q4 2024, with total expenses amounting to $1.83 million. This indicates that the company experienced a net loss of approximately $0.11 million for the quarter. The negative impact of expenses on the net income can be attributed to the high expenses incurred by the company during the quarter.

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB,aC,aD,aE,aF,aG,aH){return {layout:"default",data:[{noData:b,currentQuestion:g,textDescription:L,comeFrom:"AInvestShareLink",events:[],answerSource:n}],fetch:{},error:o,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:i,agent_id:a,output_media_info:[],task_id:a,language:a,source:n,cache_builder:a,reply_action:"Answer",execute_mode:A,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did XLO's expenses trend impact its Q4 2024 revenue?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did XLO's expenses trend impact its Q4 2024 revenue?\",\"user_id\":\"dp03536554\",\"user_name\":\"\",\"trace_id\":\"a4659214-2626-46eb-a37e-e4564618ab54\",\"session_id\":\"a4659214-2626-46eb-a37e-e4564618ab54\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:B,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue[20241231]|Total Expenses[20241231]|\n|---|---|---|---|---|---|\n|XLO|Xilio Therapeutics|$0.72|8.03%|$1.72 million||\n",query_data:{number:i,title:C,query_type:B,condition:a,model_sql:M,data_ext_params:{merge_repeat:b,expand_index:c,data_add:i,add_index:e}}}],answer_chain_name:N,agent_mode:O,native_answer:a,come_from:a,text_answer:L,trace_id:j,cost:17543,event_names:a,question:g,fallback_type:P,input_type:Q,fall_back_reason:{fall_back_type:P,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:j,first_return_cost:3386,cache_type:"no_cache",question_id:j,transfer_question:g,signal_type:"ON_COMPLETE",start_time:D,remote_svc:n,slots:[],answer_type:A,user_id:x,skill_name:E},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:j,session_id:j,user_id:x,question:g,source:n,raw_question:g,version:"3.4.1",action_name:E,nlu:{entity:[{type:R,value:S,market:F}]},output_time:D,deep_research:b,deep_thinking:b,agent_mode:O},extra:{}},{answer_path:p,section:{id:q,info_texts:["Thinking"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"begin"},logs:[],extra:{is_deep_research:b,deep_thinking:b}},{answer_path:p,section:{id:q,info_texts:["Querying Stock: XLO Revenue, Expenses in Fiscal 2024 Q4"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:T},logs:[],extra:{action:"Querying Stock",action_input:C,thought:U}},{answer_path:p,section:{id:q,info_texts:["Searching Web: Impact of Expenses on Revenue of XLO in Fiscal 2024 Q4"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:T},logs:[],extra:{action:"Searching Web",action_input:"Impact of Expenses on Revenue of XLO in Fiscal 2024 Q4",thought:U}},{answer_path:d,section:{id:s,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:p,section:{id:q,info_texts:["Generating Answer"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:t,voice_txt:"X",text_answer:V,rich_text:V,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:t,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:C,query_type:B,trace_data:a,index:i,model_sql:M,data_ext_params:{merge_repeat:b,expand_index:c,data_add:i,add_index:e},jump_type:"data_query"}],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:t,voice_txt:". This",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:X,market_id:F,name:Y,domain:R},pos:e,section_id:l,txt:Y,jump_type:"pos_fenshi"}],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:t,voice_txt:"\n",text_answer:Z,rich_text:Z,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:_,choice:[],result_page:{components:[{category:$,puuid:aa,request_config:[{related_name:ab,source_type:G}],show_type:ac,tag:"Analyst Estimate Earnings",uuid:ad,title_config:{config:{display:b,display2:b,txt_style:e,type:ae,url:a},data:{h1:a,h2:a},show_type:af}}],global:{interface_request_list:[],lowcode_json:{stack:b,visible:c,childLimit:ag,label:y,type:ah,leaf:b,animate:[],version:ai,script:[],props:{test:a},path:aj,style:{"background-color":a,"box-shadow":ak,color:a,width:h,"min-height":al,position:z,height:h},isMaterial:b,id:y,needTheme:b,hasEditor:b,packed:b,events:[],child:[{stack:b,visible:c,childLimit:e,label:"财报",type:am,leaf:c,version:"0.0.1",animate:[],url:H,componentUuid:ad,script:[{name:"earnings",id:65539,content:"return {\r\n  mounted () {\r\n    window.__oversea_ainvest__ = {\r\n      ENV: \"production\"\r\n    }\r\n  }\r\n}"}],props:{title:"Earnings"},path:H,meta:{js_url:H},style:{"background-color":a,padding:"0",color:a,display:an,width:h,position:z,height:h},isMaterial:c,_id:ao,id:am,hasEditor:c,packed:b,events:[],isSetDefaultValue:c}]},lowcode_type:ap,urp_static_data:[{name:ab,value:{columns:[{index_name:aq,key:aq,type:f},{index_name:ar,key:ar,type:f}],dataSize:i,datas:[{code:X,market_code:F}]}},{name:"advance_custom_visual",value:{columns:[{index_name:as,key:as,type:f},{index_name:at,key:at,type:f},{index_name:au,key:au,type:f}],dataSize:i,datas:[{stock_code:S,start_date:"2024-01-01",end_date:"2024-12-31"}]}}]},page:{layout:{layout_data:"[{\"uuid\":\"gyyEarnings\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:I,uuid:aa,voice_txt:a}},tag_info_list:[],is_last:b,uuid:"ebc2fd66-deb6-4303-a648-f83b26f2df61"},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:t,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:p,section:{id:q,info_texts:["Completed"],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:_,choice:[{display_text:u,query_text:u,trace_info:{item_id:"1d86bb5598834fd1189e797342997e91",item_type:m,item_name:u,rec_info:av}},{display_text:v,query_text:v,trace_info:{item_id:"7b1d31c3f5f6adece218887f92e5cf1e",item_type:m,item_name:v,rec_info:aw}},{display_text:w,query_text:w,trace_info:{item_id:"cd73116dc1df2b5b68ae020858933b89",item_type:m,item_name:w,rec_info:ax}}],result_page:{components:[{show_type:ac,title_config:{show_type:af,data:{h1:a,h2:a},config:{display:b,txt_style:e,type:ae,display2:b,url:a}},request_config:[{source_type:G,related_name:ay}],puuid:J,tag:a,category:$,uuid:az}],global:{urp_static_data:[{name:ay,value:{status_code:e,columns:[{type:f,index_name:aA,key:aA},{type:f,index_name:aB,key:aB},{type:f,index_name:aC,key:aC},{type:f,index_name:aD,key:aD},{type:f,index_name:aE,key:aE}],datas:[{send_text:u,item_type:m,rec_info:av,display_text:u,rec_reason:a},{send_text:v,item_type:m,rec_info:aw,display_text:v,rec_reason:a},{send_text:w,item_type:m,rec_info:ax,display_text:w,rec_reason:a}],dataSize:G,status_msg:a}}],lowcode_type:ap,interface_request_list:[],lowcode_json:{stack:b,visible:c,childLimit:ag,label:y,type:ah,leaf:b,animate:[],version:ai,script:[],props:[],path:aj,isTransparent:c,style:{"background-color":a,"box-shadow":ak,color:a,width:h,"min-height":al,position:z,height:h},isMaterial:b,id:y,needTheme:b,hasEditor:b,packed:b,events:[],child:[{readmeUrl:"https:",stack:b,visible:c,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:c,version:"1.12.0",animate:[],url:K,componentUuid:az,script:[{name:aF,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:c,renderType:"blue"},path:K,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:K},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:an,width:h,position:z,height:h},isMaterial:c,_id:ao,id:aF,hasEditor:c,packed:b,events:[],isSetDefaultValue:c}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:I,voice_txt:a,tracking_info:{},uuid:J},order:{is_auto:b,render_for:I,chart_type:"command",puuid:J}},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{action_name:E,with_paid_index:b,no_refresh_answer:b,answer_source:{agent_id:a,agent_name:a,execute_mode:A,answer_chain_name:N},is_deep_research:b,deep_thinking:b,create_time:1746739126878},is_last:c}],questionItem:{data:{qStr:g,encodeFlag:b,imageData:o,docsData:[],quoteData:o},tplType:"question"},events:aG,agentId:a,param:{entity_info:{},add_info:{ori_question:g},event_list:aG,client_ip:a,question:g,user_id:x,user_name:a,trace_id:j,session_id:j,source:n,input_type:Q}}],userId:x,userName:a,startTime:D,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:o,endSignal:b,theme:"white",showTracePopup:b,traceListData:[],chatTraceTargetIndex:e,traceTableData:o,showMask:b}},serverRendered:c,routePath:"\u002Faime\u002Fshare\u002Fhow-did-xlos-expenses-trend-impact-its-q4-2024-revenue-6d9dd2\u002F",config:{_app:{basePath:aH,assetsPath:aH,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",false,true,"other\u002FopenAnswer",0,"STR","How did XLO's expenses trend impact its Q4 2024 revenue?","auto",1,"a4659214-2626-46eb-a37e-e4564618ab54","signal",2001,"llm_generated","ths_ainvest_lite_web",null,"progress\u002Fsearching_for",1000,"searching_for",999,"rich_text","What were XLO's key expense categories in Q4 2024?","What was the growth rate of XLO's revenue in Q4 2024?","How did XLO's cost control efforts affect its Q4 2024 expenses?","dp03536554","root","relative","agent","intusstock","XLO Revenue, Expenses in Fiscal 2024 Q4",1746739109335,"explain news events","185",3,"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002Fearnings\u002F0.0.1\u002Fearnings@0.0.1index.js","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Xilio Therapeutics (XLO) reported total revenues of $1.72 million for Q4 2024, with total expenses amounting to $1.83 million. This indicates that the company experienced a net loss of approximately $0.11 million for the quarter. The negative impact of expenses on the net income can be attributed to the high expenses incurred by the company during the quarter.\n\n","select   stock_code,   total_revenue,   total_expenses from   ustock_fin_data where   fiscal_date = date('2024y4q')   and stock_code = 'XLO.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","XLO.O","thinking","The user wants to know how XLO's expenses trend impacted its Q4 2024 revenue. I should focus on XLO's revenue, expenses data and market analysis of the impact of these data on revenue. I will use FinQuery for the data mentioned above; use Search for the analysis.","Xilio Therapeutics (XLO) reported total revenues of $1.72 million for Q4 2024, with total expenses amounting to $1.83 million[^1]",". This indicates that the company experienced a net loss of approximately $0.11 million for the quarter. The negative impact of expenses on the net income can be attributed to the high expenses incurred by the company during the quarter.\n\n","XLO","Xilio Therapeutics","\n``` visual\n{\"uuid\":\"ebc2fd66-deb6-4303-a648-f83b26f2df61\"}\n```","result_page","custom","39192","code_entity","lowcode","gyyEarnings","1","title1",9999,"thslc\u002Fthslc-common-container","1.0.1","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js","0px 0px 0px","100%","iwencai\u002Fearnings","block",19,"shunda","market_code","code","stock_code","end_date","start_date","2+679_496_21_554+0+0+a4659214-2626-46eb-a37e-e4564618ab54+1d86bb5598834fd1189e797342997e91+llm_generated+aimeTagAnalysis+0+0.017821557819843292+1","2+679_496_21_554+0+0+a4659214-2626-46eb-a37e-e4564618ab54+7b1d31c3f5f6adece218887f92e5cf1e+llm_generated+aimeTagAnalysis+0+0.014256775379180908+2","2+679_496_21_554+0+0+a4659214-2626-46eb-a37e-e4564618ab54+cd73116dc1df2b5b68ae020858933b89+llm_generated+aimeTagAnalysis+0+0.008814145810902119+3","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>